Helicobacter pylori Prevalence and Impact: A Histology-Based Report About Children from an Endemic Country

This article was published in the following Dove Press journal:
International Journal of General Medicine

Fareed Khadair Ahmad¹
Tariq N Aladily²
Motaz Altamimi³
Maher Ajour³
Nisreen Alsaber³
Mohamed Rawashdeh¹

¹Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, School of Medicine, The University of Jordan, Amman, Jordan; ²Department of Pathology, School of Medicine, The University of Jordan, Amman, Jordan; ³Department of Pediatrics, School of Medicine, The University of Jordan, Amman, Jordan

Background: *Helicobacter pylori* is spreading worldwide with a high prevalence rate in the developing countries. Our primary goal was to measure the histology-based prevalence of *Helicobacter pylori* infection in children and to quantify its impact on the gastric inflammation and anemia. Our secondary goal was to study possible predictors for the presence of *Helicobacter pylori* in this cohort.

Methods: A retrospective chart review was performed for children who underwent Esophago-gastro-duodenoscopy at Jordan university hospital in Jordan from 2008 to 2016. Data collected included epidemiological data, indication for endoscopy, endoscopic findings, and laboratory data. The gastric biopsies were re-examined by a pathologist to check for the presence of *Helicobacter pylori*, the presence of gastritis, and to grade gastritis according to the updated Sydney criteria.

Results: A total of 98 children (53 girls–54%) underwent Esophago-gastro-duodenoscopy. The average age was 11.7 years $\pm$ 4.7 years. Of them, 53 patients (29 boys–55%) had *Helicobacter pylori* identified in the gastric biopsy. The histology-based prevalence rate of *Helicobacter pylori* was 54%. The most common indication for endoscopy was abdominal pain (53%) followed by vomiting (18%). Nodular gastric mucosa was present in 43% of the *Helicobacter pylori*-positive group, and in only 11% of the *Helicobacter pylori*-negative group (P-value <0.05). Moderate to severe chronic gastritis was seen in 59% of the biopsies of *Helicobacter pylori*-positive group, compared to 31% in the *Helicobacter pylori*-negative group (p value <0.05). Presence of anemia was not different between the two groups (p value > 0.05). Presence of endoscopic nodularity, active gastritis by histology, and moderate to severe gastritis by histology were positive predictors for the presence of *Helicobacter pylori*. (p value <0.05).

Conclusion: *Helicobacter pylori* infection in this study cohort of Jordanian children is common, with a histology-based prevalence rate of 54%. Nodularity of the stomach is the most common positive endoscopic feature, and its presence predicts the presence of *Helicobacter pylori*. Moderate to severe active gastritis is associated with *Helicobacter pylori*. The presence of *Helicobacter pylori* does not affect anemia status in this cohort of Jordanian children.

Keywords: *Helicobacter pylori*, Jordan, children, histology

Introduction

Helicobacter pylori (*H. pylori*) is spread worldwide, with a high prevalence rate in the developing countries.¹ It causes gastritis; gastric and duodenal ulcers; gastric cancer; and mucosa-associated lymphoid tissue (MALT) lymphoma.^{2–5} It is classified by the World Health Organization as a group 1 carcinogen for gastric

Correspondence: Fareed Khadair Ahmad
Email fareedpeds@yahoo.com

adenocarcinoma in adults.⁶ Unless treated during childhood, *H. pylori* infection will persist and continue till adulthood causing the above mentioned sequel.^{2,3} Its prevalence varies among developed and developing countries, ranging (34.7–82%),^{1,7} with a unique age-specific prevalence pattern in the developing countries manifesting with higher prevalence rates in adults compared to children.¹

Several diagnostic tests are used to detect *H. pylori* infection,⁸ with the initial diagnosis in children involving endoscopy and histological evaluation.^{5,9} Endoscopic findings in *H. pylori* infection in children are variable, with nodular gastric mucosa being a characteristic finding in the high prevalence countries.^{10,11} Describing histological specimens containing *H. pylori* is variable,⁸ with the updated Sydney classification widely used in adults for this purpose.^{12,13} The classification grades the stomach biopsy in regard to 4 domains: chronicity (based on presence of lymphocytes); activity (based on presence of neutrophils), glandular atrophy; and metaplasia.^{12,14}

H. pylori infection in children has been linked to several extra gastric effects; including iron deficiency anemia (IDA), idiopathic thrombocytopenic purpura (ITP), subnormal growth, short stature, diarrhea, diabetes mellitus, and recently atopy.^{15–20} The relation of *H. pylori* to IDA has been widely studied, but the findings are still conflicting.^{5,9,18,19}

Limited data exist about histology-based prevalence (HBP) of *H. pylori* in Arab children. Studies from Kuwait, Saudi Arabia, Egypt, and Oman showed the prevalence of *H. pylori* to be 31%, 62%, 65% and 25 %, respectively.^{21–24} In Jordan, studies estimated the HBP of *H. pylori* in adults to be 68%–82%,^{7,25,26} and the presence of *H. pylori* infection was documented in 50–79% of gastric cancer biopsies in adult Jordanians.^{27,28} Serology - based studies in asthmatic and healthy Jordanian children estimated *H. pylori* prevalence to range from 18.1% to 55.5%, respectively.^{20,29} One study in dyspeptic children from northern Jordan estimated the HBP to be 82%.³⁰

This study aimed to measure, the HBP of *H. pylori* in symptomatic Jordanian children, and to quantify the impact of *H. pylori* infection on the gastric inflammation and anemia. Our secondary goal was to study possible predictors for *Helicobacter pylori* presence in this cohort.

Methods

This was a retrospective chart review study. Children who underwent esophageo-gastro-duodenoscopy (EGD) at the Jordan University Hospital (JUH) between January 2008 and January 2016 were enrolled. Ethical approval was

obtained from the institutional review board (IRB) committee at the school of medicine, University of Jordan, Amman, Jordan, and from the IRB committee at JUH.

JUH is a 600-bed tertiary hospital located in Amman city, the capital of Jordan. JUH has about 500,000 yearly patient visits to the outpatient department and about 100,000 yearly visits to the emergency room. Patients come to JUH from all regions of the country but mainly from Amman and central Jordan, which represent the highest population density in the country.

Children aged 1 to 18 years who had EGD done at JUH during the study period were included. Both clinic and hospitalized patients were included in the study. Children who had gastric biopsy obtained at the time of endoscopy were included. Any child who had biopsies and endoscopy done more than once was counted as one unique patient. Children were excluded if their endoscopy or biopsy report were missing from the medical file, or if the gastric biopsy slides were missing. Children known to have the following gastrointestinal diseases were excluded: inflammatory bowel disease IBD; celiac disease; or eosinophilic esophagitis EoE. Children with other nationalities, who had EGD done at JUH during the study period, were excluded from the study.

Data collected about study subjects included age at the time of EGD; gender; residence location; usage of proton pump inhibitors (PPI); indication(s) for endoscopy; endoscopy findings as reported in the endoscopy report; and complete blood count done within 3 months from endoscopy.

Over the study period, EGDs were performed by two pediatric gastroenterologists (MR and FKA) under either general anesthesia or sedation. Biopsies were obtained from the gastric antrum and/or the gastric body, with at least two biopsies were taken from each site. Gastric biopsies were submitted for histology, placed in slides, stained with hematoxylin and eosin stain (Abbey Color, Philadelphia, PA, USA), and were assessed, at the time of endoscopy, by a pathologist. The pathologist organized a report about the findings, and it was kept in the patient's medical file. The same biopsy slides were examined again at the time of this study by an expert pathologist (TA), who was blinded to the initial pathology report. He looked for the presence of gastritis and *H. pylori* according to the updated Sydney classification. Results of his new report and old report were compared.

To ensure data privacy, each study subject was assigned a unique study number. This number was linked to the subject's clinical data. The list containing study subject names with their assigned numbers was kept in a password-protected MS-word file, which was kept on a password - protected

computer used only by the primary investigator (FKA). Clinical data was initially recorded on an intake sheet for each de-identified study subject, and then was entered on excel spread sheet. This sheet was password - protected and kept at FKA computer.

Descriptive statistics were used to describe the demographic data. For categorical variables, frequencies and percentages were reported. Comparisons of categorical variables were carried out using Pearson's chi-square test. Possible predictors of *H. pylori* presence were assessed using logistic regression analysis for each independent (predicted) variable. An a priori two-tailed level of significance was set at 0.05 levels. Statistical analyses were conducted using statistical Package for the Social Sciences version 20 (SPSS Inc. Chicago, IL, USA).

Results

A total of 228 children had EGD with gastric biopsies taken during the study period. 58 were excluded due to missing biopsy slides; 30 were excluded due to missing clinical data; 18 were excluded due to missing endoscopy or biopsy report; and 12 children were excluded due to prior diagnosis of IBD, celiac disease, or EoE. Three children had EGD done twice, so they were counted as three unique patients instead of six. Another 9 children were excluded because they were non-Jordanian nationals. The total study cohort was 98. Table 1 summarizes the study population characteristics.

The HBP of *H. pylori* in this study cohort of 98 children was 54%. Table 2 demonstrates the details of demographic findings. The majority of *H. pylori*-positive children were boys; older than 10 years of age; and lived in central Jordan. There was a progressive increment of *H. pylori* prevalence with age in this study cohort (Figure 1). The majority of *H. pylori* negative children were taking PPI at the time of endoscopy, 32 children out of 45 (%71). No significant difference was found in the prevalence of anemia in regard to the presence or absence of *H. pylori* infection. This is illustrated in Table 2.

Abdominal pain was the most common indication for endoscopy, but it was not statistically different between the group which had *H. pylori* and the group that did not (p value > 0.05). None of the other indications for endoscopy was significant either. Table 3 lists all indications for endoscopy. Several patients had more than one indication for endoscopy.

The majority of the study cohort had normal endoscopy findings (Table 4). Nodularity of the gastric mucosa was seen in 43% of the *H. pylori*-positive group and only in

Table 1 Demographic Data of the Study Population

Character	Number (%)
Total number	98
Gender	
Male	45(46)
Female	53(54)
Age range	1 year – 18 years
Mean $\pm$ SD	12.1 years $\pm$ 4.6 years
Age group distribution	
<5 years	9 (9)
5-10 Years	27 (28)
>10 years	62 (63)
Residence	
Northern Jordan ^a	5 (5)
Central Jordan ^b	91 (93)
Southern Jordan ^c	2 (2)
Medications: Proton pump inhibitors	34 (35)

Notes: ^aNorthern Jordan: includes the districts of Irbid, Ajloun, Jerash, and Mafrq.

^bCentral Jordan includes the districts of Amman (the capital), Balqa, Zarqa, and Madaba. ^cSouth Jordan includes the districts of: Ma'an, Kerak, Tafilah, and Aqaba.

11% of the *H. pylori* negative group. This was statistically significant, with p-value <0.05. Stomach ulcers were seen in only 3 (3%) children, but only one of them had *H. pylori*. Ulcers in the other 2 children were due to non-steroidal anti-inflammatory drugs (NSAID) ingestion.

Based on the updated Sydney classification of gastritis, two thirds of children who had *H. pylori* had moderate to severe chronic gastritis, whereas two thirds of those who did not have *H. pylori* had absent to mild chronic gastritis (Table 5). Moderate chronic gastritis was statistically higher in the *H. pylori* positive group (p value <0.05). The presence of *H. pylori* was significantly associated with active gastritis (p value <0.05). Glandular atrophy and intestinal metaplasia were rarely seen in this children cohort. There was a 100% concordance between the initial pathology report at the time of endoscopy and the one reproduced during this study.

Using logistic regression to evaluate for possible predictors for *H. pylori* (Table 6), the presence of nodularity by endoscopy, and the presence of active gastritis by histology were statistically significant variables (p value < 0.05).

Discussion

This is the first histology-based study about *H. pylori* prevalence and impact on Jordanian children. The prevalence

Table 2 Demographic Data of *H. pylori* in Jordanian Children

Character	<i>H. pylori</i> Positive N (%)	<i>H. pylori</i> Negative N (%)	P value
Total number	53(54)	45 (46)	0.482
Gender			
Male	29(55)	16(36)	0.077
Female	24(45)	29(64)	0.686
Age			
Mean (range) in years	12.2 (1–18)	12 (2–18)	1.000
± SD	4.8	4.6	
< 5 years	3(6)	6(13)	0.480
5–10 years	16(30)	11(24)	0.317
>10 years	34(64)	28(63)	0.446
Northern Jordan ^a	4	1	0.180
Central Jordan ^b	49	42	0.463
Southern Jordan ^c	0	2	–
Medications: Proton pump inhibitors	2	32	0.000
Anemia: HGB less than 11 mg/ dl	5(9)	7(16)	0.564

Notes: ^aNorthern Jordan: includes the districts of Irbid, Ajloun, Jerash, and Mafraq. ^bCentral Jordan includes the districts of Amman (the capital), Balqa, Zarqa, and Madaba. ^cSouth Jordan includes the districts of Ma'an, Kerak, Tafilah, and Aqaba.

rate was 54% among symptomatic children, and it compares to the rates in the literature from other Arab countries.^{21–24}

Table 7 summarizes these histology-based studies. Jordan's

high prevalence rate is similar to those of Egypt and Saudi Arabia and almost double those of Oman and Kuwait.

In comparison to Jordanian adult prevalence rate of 82%, the HBP of *H. pylori* in Jordanian children is not as high.⁷ The majority of cases in children were above 10 years of age, with a low prevalence of *H. pylori* among children less than 5 years of age (Table 2). This supports the data about acquisition of *H. pylori* infection in developing countries during childhood, and higher infection rates in adults.^{1,23} The high prevalence rate of *H. pylori* infection in Jordanian children, along with the high rate of *H. pylori* related gastric cancer in adult Jordanians,²⁸ makes *H. pylori* eradication an important childhood issue. *H. pylori* infection is related to the socioeconomic status, sanitation level, living standards and the overall health level in the country.³¹ This is reflected by the ongoing decline in *H. pylori* and gastric cancer prevalence rates in the developed countries.^{32,33}

It is likely, though, the prevalence rate of *H. pylori* in Jordanian children could be higher than what is revealed by our study. This could be attributed to several culprits. The majority of children who did not have *H. pylori* in this study (70%) were on medications that can decrease the detection rate of *H. pylori*, like proton pump inhibitors (PPI). Others might have been on antibiotics week(s) before endoscopy. Further, no special stains, like Giemsa, were done to look for *H. pylori*, and histology was the only criterion used to confirm *H. pylori* presence. Other tests, like rapid urease test, serology, or tissue culture, were not implemented at the time of endoscopy.

Figure 1 Age distribution of *H. pylori*-positive children.

Table 3 Frequency of Endoscopy Indications in the Study Population

Indication ^a	Frequency of Endoscopy Indication			P value ^c
	Study Population N ^b (%)	<i>H. pylori</i> Positive N ^b (%)	<i>H. pylori</i> Negative N ^b (%)	
Abdominal pain	80 (53)	42 (53)	38 (54)	0.655
Vomiting	26 (18)	15 (18)	11 (17)	0.433
Constipation	10 (7)	3 (4)	7 (10)	0.206
Abdominal distension	7 (5)	5 (6)	2 (4)	0.257
Weight loss	10(7)	5 (7)	5 (7)	1.000
Diarrhea	4 (3)	3 (4)	1 (1)	0.317
Positive celiac serology	5 (3)	3 (4)	2 (2)	0.655
Others				
Hematemesis	2 (1)	1 (1)	1 (1)	1.000
Melena/positive heme occult	2(2)	1 (1)	1 (2)	1.000
Recurrent oral ulcers	2(1)	1 (1)	1 (1)	1.000
Caustic ingestion	2(1)	1 (1)	1 (1)	1.000
Number of endoscopy indications	150 (100)	80 (100)	70 (100)	0.414

Notes: ^aSome patients had more than one indication for endoscopy. ^bRefers in this table to the number of indications for endoscopy in this group (symptom or sign). ^cBetween *H. pylori* positive and *H. pylori* negative groups.

The HBP rate in our study was lower than that conducted by Shatnawi et al in Jordanian children.³⁰ This can be explained in part by the factors mentioned in the preceding paragraph. In addition, Shatnawi et al studied only dyspeptic children who lived in northern Jordan, whereas our study looked at dyspeptic and other children, who underwent upper endoscopy from central Jordan. It is possible that the geographical factor contributes to HBP in Jordanian children. Further studies are needed to answer this question.

Table 4 Endoscopic Findings in the Study Population

Endoscopic Finding	<i>H. pylori</i> Positive N (%)	<i>H. pylori</i> Negative N (%)	P value
Normal endoscopy	22(42)	33(74)	0.174
Nodularity	23(43)	5(11)	0.001
Erosions	7(13)	5(11)	0.564
Ulcers	1(2)	2(4)	0.564

Table 5 Histology Descriptions Based on Updated Sydney Classification

		<i>H. pylori</i> Positive N (%)	<i>H. pylori</i> Negative N (%)	P value
Chronic inflammation	Absent	0(0)	7(16)	–
	Mild	22(41)	24(53)	0.768
	Moderate	21(40)	8(18)	0.016
	Sever	10(19)	6(13)	0.317
Polymorph nuclear cell activity	Absent	25(47)	36(80)	0.159
	Present	28(53)	9(20)	0.002
Glandular atrophy	Present	2(4)	0 (0)	–
	Absent	51 (96)	45(100)	0.540
Metaplasia	Present	2(4)	0(0)	–
	Absent	51 (96)	45(100)	0.540

Despite the known shortcomings of serology testing, the prevalence of *H. pylori* in this histology -based study is close to the prevalence rate found by a prior serology-based study from Jordan.²⁹ Using enzyme-linked immunosorbent assay (ELISA) for detection of serum IgG and IgA antibodies against *H. pylori* in 200 children, Bani-Hani et al reported a prevalence of *H. pylori* in healthy schoolchildren to be 55.5%. Although practice guidelines from the European and North American Society for pediatric gastroenterology, hepatology, and nutrition (ESPGHAN and NASPGHAN) advice against using serology testing for initial diagnosis of *H. pylori* infection in a clinical setting,^{5,9} we find in this study that there is a good correlation between our histology-based study and the prior serology-based study. The ESPGHAN/NASPGHAN recommendation is based on the low performance of serology testing in most European and North America countries, which is due to the low disease prevalence there.^{5,9} Known limitations for serology testing include its inability to differentiate ongoing from old infection and the lag of positive testing behind the clinical condition.⁸

The majority of *H. pylori*-infected children in our study lived in central Jordan. This includes the districts of Amman (the capital of Jordan); Balqa, Zarqa; and Madaba. Few children lived in northern and southern Jordan. We believe this is due to the referral bias to our institution, which captures the majority of its patients from central Jordan. More studies at the national level are needed to verify the accurate epidemiology and distribution of *H. pylori* infection in Jordanian children. Although more boys than girls had *H. pylori* infection in this study

Table 6 Variables Predictors for *H. pylori* Infection

Independent Variable		R	R Square	F	Sig.	Beta Unstandardized	t	Sig.
Demographic data	Age	.046 ^a	.002	.207	.650 ^a	.005	.455	.650
	Gender	.192 ^a	.037	3.659	.059 ^a	-.192-	-1.913-	.059
Indication for endoscopy	Abdominal pain	.018 ^a	.0001	.033	.857 ^b	.016	.181	.857
	Vomiting	.018 ^a	.0001	.033	.857 ^b	-.016	-.181	.857
Laboratory data	Anemia	.178 ^a	.032	3.124	.080 ^b	.049	1.768	.080
Endoscopy finding	Nodules	.356 ^a	.127	13.945	.000 ^b	.393	3.734	.000
	Erosions	.059 ^a	.003	.330	.567 ^b	.086	.574	0.567
	Ulcers	.074 ^a	.005	.528	.469 ^b	-.214-	-.727-	0.469
Updated Sydney classification	Chronicity	.069 ^a	.005	.449	.504 ^a	-.043-	-.670-	.504
	Activity	.304 ^a	.093	9.801	.002 ^a	-.290-	-3.131-	.002
	Atrophy	.133 ^a	.018	1.729	.192 ^a	-.469-	-1.315-	.192
	Intestinal metaplasia	.133 ^a	.018	1.729	.192 ^a	-.469-	-1.315-	.192

Note: ^aDependent Variable: *H. pylori*.

(55% vs 45%), this was not statistically significant. Zamani et al's meta-analysis showed no gender difference in worldwide *H. pylori* prevalence,¹ whereas Ibrahim et al recently in his meta-analysis showed a slight male predominance.³⁴ More studies are needed to clarify any gender differences.

Although abdominal pain was the most common indication for endoscopy, it was not statistically different between children who had *H. pylori* infection and those that did not (p-value 0.2). This is likely due to the low prevalence of stomach ulcers in our study (Table 4). The NASPGHAN/ESPGHAN guidelines indicate that *H. pylori* causes abdominal pain in children only when ulcers are present.^{5,9} This is also supported by the finding that the prevalence rate of *H. pylori* in this study of symptomatic children was close to its prevalence in the study of healthy schoolchildren in Jordan, with a rate of 54% and 55.5%, respectively.²⁹

Our study did not find a difference in the prevalence of anemia in the presence or absence of *H. pylori* infection. This might be due to small sample size and low prevalence of anemia in the whole cohort (13%). Due to the

retrospective nature of this study and absent laboratory data, no analysis could have been performed regarding the type of anemia these children had, or to do the correlation between iron stores before and after treatment. Prospective studies can help in finding the answer to this important question.^{18,19}

Our study suffers from a few limitations. The retrospective nature of the study prohibited the evaluation of specific diagnostic methods like Giemsa staining, rapid urease test or tissue culture. It did not allow stopping PPI or antibiotics around the time of endoscopy, and made it difficult to assess the success of *H. pylori* identification, eradication, or effect on patients' symptoms or investigations. The study took JUH as the only site for the study, which resulted in the majority of the study population coming from central Jordan. More studies at the country level will provide a better understanding of the disease demography. Moreover, this study was not a mass screening study for all children in Jordan, but rather for the symptomatic ones who were referred to JUH. The result of our study should be interpreted in this

Table 7 Histology-Based Prevalence of *H. pylori* in Arab World Countries

year	Author	Country	<i>H. pylori</i> Prevalence	No. of Children	Status of Cohort
1993	Radhakrishnan ²¹	Kuwait	31%	60	Symptomatic + healthy
2005	El-Mouzan ²²	Saudi Arabia	65%	175	Symptomatic
2013	El-Mazary ²⁴	Egypt	65%	70	Symptomatic
2014	Al-sinani ²³	Oman	25%	112	Symptomatic
2015	Shatnawi ³⁰	Jordan	82%	163	Symptomatic
2019	Khdair Ahmad	Jordan	54%	98	Symptomatic

context. Prospective screening studies at the country level looking for eradication rates of *H. pylori*, treatment regimen, and antibiotic sensitivity are needed.

Antibiotics use was not looked at in this study. Antibiotics in Jordan are given sometimes without a prescription in the private sector, and their use or its absence was not recorded routinely in all medical charts. Due to the retrospective nature of the study, it was difficult to track those who had antibiotics from those who did not. Future prospective studies should address this important issue.

Conclusion

In conclusion, *H. pylori* infection among Jordanian children is common, with a prevalence rate reaching, at least, 54% in symptomatic children from central Jordan. Its prevalence tends to increase with age. Nodularity of the stomach is the most common positive endoscopic finding of its presence. Stomach ulcers were rare in this cohort. Moderate to severe active gastritis are associated with *Helicobacter pylori* in Jordanian children. The presence of *Helicobacter pylori* did not affect anemia status in this cohort of Jordanian children. Prospective studies at the country level are needed.

Ethical Approval

Ethical approval was obtained from IRB committee at the school of medicine, University of Jordan, Amman, Jordan, and from the IRB committee at Jordan university hospital.

Acknowledgment

This research was funded by a grant from the University of Jordan – deanship of academic research; grant number 33/2015–2016.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Zamani M, Ebrahimitabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2018;47(7):868–876. doi:10.1111/apt.14561
2. Valle J, Kekki M, Sipponen P, Ihmaki T, Siurala M. Long-term course and consequences of *Helicobacter pylori* gastritis. Results of a 32-year follow-up study. *Scand J Gastroenterol.* 1996;31(6):546–550. doi:10.3109/00365529609009126
3. Xia HH, Talley NJ. Natural acquisition and spontaneous elimination of *Helicobacter pylori* infection: clinical implications. *Am J Gastroenterol.* 1997;92(10):1780–1787.
4. Cave DR. Transmission and epidemiology of *Helicobacter pylori*. *Am J Med.* 1996;100(5a):12S–17S; discussion 17S–18S. doi:10.1016/S0002-9343(96)80224-5
5. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for *Helicobacter pylori* infection in children. *J Pediatr Gastroenterol Nutr.* 2011;53(2):230–243. doi:10.1097/MPG.0b013e3182227e90
6. Schistosomes, liver flukes and *Helicobacter pylori*. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. *IARC Monogr Eval Carcinog Risks Hum.* 1994;61:1–241.
7. Bani-Hani KE, Hammouri SM. Prevalence of *Helicobacter pylori* in Northern Jordan. Endoscopy based study. *Saudi Med J.* 2001;22(10):843–847.
8. Guarner J, Kalach N, Elitsur Y, Koletzko S. *Helicobacter pylori* diagnostic tests in children: review of the literature from 1999 to 2009. *Eur J Pediatr.* 2010;169(1):15–25. doi:10.1007/s00431-009-1033-x
9. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of *Helicobacter pylori* in children and adolescents (update 2016). *J Pediatr Gastroenterol Nutr.* 2017;64(6):991–1003. doi:10.1097/MPG.0000000000001594
10. Bahu Mda G, da Silveira TR, Maguinnick I, Ulbrich-Kulczynski J. Endoscopic nodular gastritis: an endoscopic indicator of high-grade bacterial colonization and severe gastritis in children with *Helicobacter pylori*. *J Pediatr Gastr Nutr.* 2003;36(2):217–222. doi:10.1097/00005176-200302000-00011
11. Elitsur Y, Raghuverra A, Sadat T, Vaid P. Is gastric nodularity a sign for gastric inflammation associated with *Helicobacter pylori* infection in children? *J Clin Gastroenterol.* 2000;30(3):286–288. doi:10.1097/00004836-200004000-00016
12. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated sydney system. International workshop on the histopathology of Gastritis, Houston 1994. *Am J Surg Pathol.* 1996;20(10):1161–1181. doi:10.1097/00000478-199610000-00001
13. Dixon MF, Genta RM, Yardley JH, Correa P. Histological classification of gastritis and *Helicobacter pylori* infection: an agreement at last? The international workshop on the histopathology of gastritis. *Helicobacter.* 1997;2(Suppl 1):S17–S24. doi:10.1111/j.1523-5378.1997.06b09.x
14. Sipponen P, Price AB. The sydney system for classification of gastritis 20 years ago. *J Gastroenterol Hepatol.* 2011;26(Suppl 1):31–34. doi:10.1111/j.1440-1746.2010.06536.x
15. Pacifico L, Osborn JF, Tromba V, Romaggioli S, Bascetta S, Chiesa C. *Helicobacter pylori* infection and extragastric disorders in children: a critical update. *World J Gastroenterol.* 2014;20(6):1379–1401. doi:10.3748/wjg.v20.i6.1379
16. Queiroz DM, Rocha AM, Crabtree JE. Unintended consequences of *Helicobacter pylori* infection in children in developing countries. *Gut Microbes.* 2013;4(6):494–504. doi:10.4161/gmic.26277
17. Poddar U. *Helicobacter pylori*: a perspective in low- and middle-income countries. *Paediatr Int Child Health.* 2019;39(1):13–17. doi:10.1080/20469047.2018.1490100
18. Qu XH, Huang XL, Xiong P, et al. Does *Helicobacter pylori* infection play a role in iron deficiency anemia? A meta-analysis. *World J Gastroenterol.* 2010;16(7):886–896. doi:10.3748/wjg.v16.i7.886
19. Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between *Helicobacter pylori* infection and iron deficiency anemia. *Helicobacter.* 2017;22:1. doi:10.1111/hel.12330
20. Albataineh E, Alnawaiseh N, Al-Zayadneh E, Al-amer R, Kaplan N, Abu-lobbad M. The relationship between *Helicobacter pylori* (*H. pylori*) and atopy and allergic diseases. *Jordan J Biol Sci.* 2018;11(2):123–128.
21. Radhakrishnan S, Al Nakib B, Kalaoui M, Patric J. *Helicobacter pylori*-associated gastritis in Kuwait: endoscopy-based study in symptomatic and asymptomatic children. *J Pediatr Gastroenterol Nutr.* 1993;16(2):126–129. doi:10.1097/00005176-199302000-00005
22. El-Mouzan MI, Abdullah AM, Al-Mofleh IA. Gastritis in Saudi Arab children. *Saudi Med J.* 2005;26(4):576–579.

23. Al-Sinani S, Sharef SW, Al-Naamani K, Al-Sharji H. *Helicobacter pylori* infection in Omani children. *Helicobacter*. 2014;19(4):306–311. doi:10.1111/hel.12134
24. El-Mazary AM, Elfoly MA, Ahmed MF, Abdel-Hamed WM, Hassan ZM. *Helicobacter pylori* infection in a group of Egyptian children with upper gastro-intestinal bleeding. *Gastroenterolo Res*. 2013;6(3):95–102. doi:10.4021/gr533e
25. Latif AH, Shami SK, Batchoun R, Murad N, Sartawi O. *Helicobacter pylori*: a Jordanian study. *Postgrad Med J*. 1991;67(793):994–998. doi:10.1136/pgmj.67.793.994
26. Shennak MM, Kilani AF. *Helicobacter pylori* in dyspeptic Jordanian patients. *Trop Gastroenterol*. 1998;19(1):15–18.
27. Awad HA, Hajeer MH, Abulihya MW, Al-Chalabi MA, Al Khader AA. Epidemiologic characteristics of gastric malignancies among Jordan University Hospital patients. *Saudi Med J*. 2017;38(9):965–967. doi:10.15537/smj.2017.9.19371
28. Abbasi SY, Taani HE, Saad A, Badheeb A, Addasi A. Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. *Gastrointest Cancer Res*. 2011;4(4):122–127.
29. Bani-Hani KE, Shatnawi NJ, El Qaderi S, Khader YS, Bani-Hani BK. Prevalence and risk factors of *Helicobacter pylori* infection in healthy schoolchildren. *Chin J Dig Dis*. 2006;7(1):55–60. doi:10.1111/j.1443-9573.2006.00245.x
30. Shatnawi M, Rawabdeh N, Al-Nahar L, Swaidat S, Jumean S, Malkawi N. *Helicobacter pylori* infection in dyspeptic children: endoscopic and histological features. *J Roy Med Serv*. 2015;22(1):52–57. doi:10.12816/0009787
31. Bruce MG, Maaros HI. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2008;13(Suppl 1):1–6. doi:10.1111/j.1523-5378.2008.00631.x
32. Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of *Helicobacter pylori* infection in children: a population-based study in Japan. *Helicobacter*. 2015;20(2):133–138. doi:10.1111/hel.12184
33. Inoue M. Changing epidemiology of *Helicobacter pylori* in Japan. *Gastric Cancer*. 2017;20(Suppl 1):3–7. doi:10.1007/s10120-016-0658-5
34. Ibrahim A, Morais S, Ferro A, Lunet N, Peleteiro B. Sex-differences in the prevalence of *Helicobacter pylori* infection in pediatric and adult populations: systematic review and meta-analysis of 244 studies. *Dig Liver Dis*. 2017;49(7):742–749. doi:10.1016/j.dld.2017.03.019

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>